Literature DB >> 16111536

Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.

Wing-Yan Au1, Clarence C K Lam, Chor-Sang Chim, Annie W K Pang, Yok-Lam Kwong.   

Abstract

Two patients with pure red cell aplasia (PRCA) refractory to anti-thymocyte globulin, prednisolone, cyclophosphamide, fludarabine, mitoxantrone, dexamethasone and cyclosporine, were treated with alemtuzumab (anti-CD52 antibody). Case 1, a 35-year-old man with idiopathic PRCA, remitted completely with 130 mg of alemtuzumab. Case 2, a 42-year-old man with PRCA due to T-cell large granular lymphocyte (T-LGL) leukaemia, achieved complete remission of the PRCA with 490 mg of alemtuzumab, although the T-LGL leukaemia responded only transiently. There were no significant side effects, and normalization of erythropoiesis was durable. Alemtuzumab is active in PRCA that is idiopathic or secondary to T-cell lymphoproliferative diseases.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16111536     DOI： 10.1016/j.leukres.2005.02.018

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  10 in total

Review 1.  The pathogenesis and treatment of large granular lymphocyte leukemia.

Authors:  Steven Nathaniel Steinway; Francis LeBlanc; Thomas P Loughran
Journal:  Blood Rev       Date:  2014-03-07       Impact factor: 8.250

2.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

3.  Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia.

Authors:  Minoru Kojima; Shinichiro Machida; Ai Sato; Mitsuki Miyamoto; Makiko Moriuchi; Yoshiaki Ohbayashi; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2013-10-26       Impact factor: 2.490

Review 4.  The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders.

Authors:  Ranran Zhang; Mithun Vinod Shah; Thomas P Loughran
Journal:  Hematol Oncol       Date:  2010-09       Impact factor: 5.271

5.  How I manage acquired pure red cell aplasia in adults.

Authors:  Carmelo Gurnari; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2021-04-15       Impact factor: 22.113

6.  Pathophysiologic Mechanisms And Management Of Large Granular Lymphocytic Leukemia Associated Pure Red Cell Aplasia.

Authors:  Zhi-Yuan Qiu; Rong Qin; Guang-Yu Tian; Yan Wang; Ye-Qing Zhang
Journal:  Onco Targets Ther       Date:  2019-10-04       Impact factor: 4.147

Review 7.  Persistent Large Granular Lymphocyte Clonal Expansions: "The Root of Many Evils"-And of Some Goodness.

Authors:  Carlos Bravo-Pérez; Salvador Carrillo-Tornel; Esmeralda García-Torralba; Andrés Jerez
Journal:  Cancers (Basel)       Date:  2022-03-05       Impact factor: 6.639

8.  Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.

Authors:  Bogdan Dumitriu; Sawa Ito; Xingmin Feng; Nicole Stephens; Muharrem Yunce; Sachiko Kajigaya; Joseph J Melenhorst; Olga Rios; Priscila Scheinberg; Fariba Chinian; Keyvan Keyvanfar; Minoo Battiwalla; Colin O Wu; Irina Maric; Liqiang Xi; Mark Raffeld; Pawel Muranski; Danielle M Townsley; Neal S Young; Austin J Barrett; Phillip Scheinberg
Journal:  Lancet Haematol       Date:  2015-12-17       Impact factor: 18.959

9.  Rational management approach to pure red cell aplasia.

Authors:  Suresh Kumar Balasubramanian; Meena Sadaps; Swapna Thota; Mai Aly; Bartlomiej P Przychodzen; Cassandra M Hirsch; Valeria Visconte; Tomas Radivoyevitch; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941

10.  T-cell large granular lymphocyte leukemia: an Asian perspective.

Authors:  Yok-Lam Kwong; Wing-Yan Au; Anskar Y H Leung; Eric W C Tse
Journal:  Ann Hematol       Date:  2010-04       Impact factor: 3.673
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.